Nathalie Aulner received her PhD in Molecular Biology from the University Paul Sabatier (Toulouse, France) after completing an engineer degree in Biochemistry and Biotechnology at the Institut National des Sciences Appliquées (Toulouse).
She joined the Institut Pasteur in 2009 to take charge of the High Content Analysis efforts in the PFID-Imagopole led by Pr. S. Shorte. Her areas of interest encompass the challenges of applying high content analysis to the study of infectious diseases, developing assays to achieve physiologically and clinically relevant conditions, live cell imaging and applying robust statistical methodologies. She is as well implicated in the facility training programs in microscopy and is the point of contact for all Health and Safety matters in the platform.
Before joining the Institut Pasteur, she worked for several years in the United States, including as an associate research scientist at the Columbia University Screening Center (New York) led by Dr J.E. Rothman and in the Functional Proteomic Project (joined ventures between the Memorial Sloan Kettering Cancer Center in New York and Amersham biosciences to set up a siRNA phenotypic screening facility).
Cliquez pour voir le graph
Connexions
Cliquez pour voir la ligne de temps
Ligne de temps
Projets
Outils
Publications
Télécharger-
2020A role for Taok2 in Listeria monocytogenes vacuolar escape., J. Infect. Dis. 2020 Jun; (): .
-
2020Targeting Macrophage Histone H3 Modification as a Leishmania Strategy to Dampen the NF-κB/NLRP3-Mediated Inflammatory Response., Cell Rep 2020 Feb; 30(6): 1870-1882.e4.
-
2020Unveiling Interindividual Variability of Human Fibroblast Innate Immune Response Using Robust Cell-Based Protocols., Front Immunol 2020 ; 11(): 569331.
-
2019Author Correction: Discovery of novel hit compounds with broad activity against visceral and cutaneous Leishmania species by comparative phenotypic screening., Sci Rep 2019 Jul; 9(1): 10148.
-
2019Next-Generation Phenotypic Screening in Early Drug Discovery for Infectious Diseases, Trends Parasitol. 2019 Jul;35(7):559-570.
-
2019Discovery of novel hit compounds with broad activity against visceral and cutaneous Leishmania species by comparative phenotypic screening, Sci Rep 2019 Jan;9(1):438.
-
2018Fluorescence imaging host pathogen interactions: fifteen years benefit of hindsight…., Curr Opin Microbiol 2018 06; 43(): 193-198.
-
2017Assessing Vacuolar Escape of Listeria Monocytogenes, Methods Mol. Biol. 2017;1535:173-195.
-
2016Screening out irrelevant cell-based models of disease, Nat Rev Drug Discov 2016 11;15(11):751-769.
-
2016From Drug Screening to Target Deconvolution: a Target-Based Drug Discovery Pipeline Using Leishmania Casein Kinase 1 Isoform 2 To Identify Compounds with Antileishmanial Activity, Antimicrob. Agents Chemother. 2016 05;60(5):2822-33.
-
+Voir la liste complète de publications